Search

Your search keyword '"Chow, Pierce K.H."' showing total 206 results
Start Over Author "Chow, Pierce K.H."
206 results on '"Chow, Pierce K.H."'

3. Esrra regulates Rplp1-mediated translation of lysosome proteins suppressed in metabolic dysfunction-associated steatohepatitis and reversed by alternate day fasting

Author

Tripathi, Madhulika, Gauthier, Karine, Sandireddy, Reddemma, Zhou, Jin, Guptta, Priyanka, Sakthivel, Suganya, Teo, Wei Wen, Naing, Yadanar Than, Arul, Kabilesh, Tikno, Keziah, Park, Sung-Hee, Wu, Yajun, Wang, Lijin, Bay, Boon-Huat, Sun, Lei, Giguere, Vincent, Chow, Pierce K.H., Ghosh, Sujoy, McDonnell, Donald P., Yen, Paul M., and Singh, Brijesh K.

Published
2024
Full Text
View/download PDF

5. IFNγ−IL-17+ CD8 T cells contribute to immunosuppression and tumor progression in human hepatocellular carcinoma

Author

Lee, Yun Hua, Chuah, Samuel, Nguyen, Phuong H.D., Lim, Chun Jye, Lai, Hannah L.H., Wasser, Martin, Chua, Camillus, Lim, Tony K.H., Leow, Wei Qiang, Loh, Tracy Jiezhen, Wan, Wei Keat, Pang, Yin Huei, Soon, Gwyneth, Cheow, Peng Chung, Kam, Juinn Huar, Iyer, Shridhar, Kow, Alfred, Bonney, Glenn K., Chan, Chung Yip, Chung, Alexander, Goh, Brian K.P., Zhai, Weiwei, Chow, Pierce K.H., Albani, Salvatore, Liu, Haiyan, and Chew, Valerie

Published
2023
Full Text
View/download PDF

9. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma

Author

Cheng, Yang, Gunasegaran, Bavani, Singh, Harsimran D., Dutertre, Charles-Antoine, Loh, Chiew Yee, Lim, Jia Qi, Crawford, Jeremy Chase, Lee, Hong Kai, Zhang, Xiaomeng, Lee, Bernett, Becht, Etienne, Lim, Wan Jun, Yeong, Joe, Chan, Chung Yip, Chung, Alexander, Goh, Brian K.P., Chow, Pierce K.H., Chan, Jerry K.Y., Ginhoux, Florent, Tai, David, Chen, Jinmiao, Lim, Seng Gee, Zhai, Weiwei, Choo, Su Pin, and Newell, Evan W.

Published
2021
Full Text
View/download PDF

10. Changing trends in the clinicopathological features, practices and outcomes in the surgical management for cystic lesions of the pancreas and impact of the international guidelines: Single institution experience with 462 cases between 1995-2018

Author

Goh, Brian K.P., Park, Rachel H.S., Koh, Ye-Xin, Teo, Jin-Yao, Tan, Ek-Khoon, Cheow, Peng-Chung, Thng, Choon-Hua, Low, Albert S., Tan, Damien M., Chow, Pierce K.H., Chan, Chung-Yip, Chung, Alexander Y.F., and Ooi, London L.P.J.

Published
2020
Full Text
View/download PDF

11. Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma

Author

Sharma, Ankur, Seow, Justine Jia Wen, Dutertre, Charles-Antoine, Pai, Rhea, Blériot, Camille, Mishra, Archita, Wong, Regina Men Men, Singh, Gurmit Singh Naranjan, Sudhagar, Samydurai, Khalilnezhad, Shabnam, Erdal, Sergio, Teo, Hui Min, Khalilnezhad, Ahad, Chakarov, Svetoslav, Lim, Tony Kiat Hon, Fui, Alexander Chung Yaw, Chieh, Alfred Kow Wei, Chung, Cheow Peng, Bonney, Glenn Kunnath, Goh, Brian Kim-Poh, Chan, Jerry K.Y., Chow, Pierce K.H., Ginhoux, Florent, and DasGupta, Ramanuj

Published
2020
Full Text
View/download PDF

14. Laparoscopic Liver Resection Difficulty Score—a Validation Study

Author

Lee, Ser Yee, Goh, Brian K.P., Sepideh, Gholami, Allen, John C., Merkow, Ryan P., Teo, Jin Yao, Chandra, Deepa, Koh, Ye Xin, Tan, Ek Khoon, Kam, Juinn Haur, Cheow, Peng Chung, Chow, Pierce K.H., Ooi, London L.P.J., Chung, Alexander Y.F., D’Angelica, Michael I., Jarnagin, William R., Peter Kingham, T., and Chan, Chung Yip

Published
2019
Full Text
View/download PDF

16. Real-World Data on the Diagnosis, Treatment, and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT Study.

Author

Sim, Yu Ki, Chong, Ming Chuen, Gandhi, Mihir, Pokharkar, Yogesh Mahadev, Zhu, Yanan, Shi, Luming, Lequn, Li, Chen, Chien-Hung, Kudo, Masatoshi, Lee, Joon Hyeok, Strasser, Simone I., Chanwat, Rawisak, and Chow, Pierce K.H.

Subjects
HEPATOCELLULAR carcinoma, TREATMENT effectiveness, DIAGNOSIS, SPECTRUM allocation, HEPATITIS B, HEPATITIS C
Abstract

Introduction: Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the third leading cause of cancer death worldwide. While there has been rapid evolution in the treatment paradigm of HCC across the past decade, the extent to which these newly approved therapies are utilized in clinical practice in the real world is, however, unknown. The INSIGHT study was an investigator-initiated, multi-site longitudinal cohort study conducted to reflect real-world epidemiology and clinical practice in Asia-Pacific in the immediate 7-year period after the conclusion of the BRIDGE study. Methods: Data were collected both retrospectively (planned 30% of the total cohort size) and prospectively (planned 70%) from January 2013 to December 2019 from eligible patients newly diagnosed with HCC from 33 participating sites across 9 Asia-Pacific countries. Results: A total of 2,533 newly diagnosed HCC patients (1,052 in retrospective cohort and 1,481 in prospective cohort) were enrolled. The most common risk factor was hepatitis B in all countries except Japan, Australia, and New Zealand, where the prevalence of hepatitis C and diabetes were more common. The top three comorbidities reported in the INSIGHT study include cirrhosis, hypertension, and diabetes. We observe high heterogeneity in the first-line treatment recorded across countries and across disease stages, which significantly affects survival outcomes. Stratification by factors such as etiologies, tumor characteristics, the presence of extrahepatic metastases or macrovascular invasion, and the use of subsequent lines of treatment were performed. Conclusion: The INSIGHT study describes a wide spectrum of clinical management practices in HCC, where patient demographics, differential costs, and patient access to therapies may lead to wide geographical variations through the patient's treatment cycle, from diagnosis to clinical outcome. The high heterogeneity in patient outcomes demonstrates the need for more robust and clinical management strategies to be designed and adopted to bring about better patient outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Supplementary Tables 1 through 13 from Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma

Author

Qamra, Aditi, primary, Xing, Manjie, primary, Padmanabhan, Nisha, primary, Kwok, Jeffrey Jun Ting, primary, Zhang, Shenli, primary, Xu, Chang, primary, Leong, Yan Shan, primary, Lee Lim, Ai Ping, primary, Tang, Qianqao, primary, Ooi, Wen Fong, primary, Suling Lin, Joyce, primary, Nandi, Tannistha, primary, Yao, Xiaosai, primary, Ong, Xuewen, primary, Lee, Minghui, primary, Tay, Su Ting, primary, Keng, Angie Tan Lay, primary, Gondo Santoso, Erna, primary, Ng, Cedric Chuan Young, primary, Ng, Alvin, primary, Jusakul, Apinya, primary, Smoot, Duane, primary, Ashktorab, Hassan, primary, Rha, Sun Young, primary, Yeoh, Khay Guan, primary, Peng Yong, Wei, primary, Chow, Pierce K.H., primary, Chan, Weng Hoong, primary, Ong, Hock Soo, primary, Soo, Khee Chee, primary, Kim, Kyoung-Mee, primary, Wong, Wai Keong, primary, Rozen, Steven G., primary, Teh, Bin Tean, primary, Kappei, Dennis, primary, Lee, Jeeyun, primary, Connolly, John, primary, and Tan, Patrick, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Text, Supplementary Figures 1 through 13, Supplementary Methods from Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma

Author

Qamra, Aditi, primary, Xing, Manjie, primary, Padmanabhan, Nisha, primary, Kwok, Jeffrey Jun Ting, primary, Zhang, Shenli, primary, Xu, Chang, primary, Leong, Yan Shan, primary, Lee Lim, Ai Ping, primary, Tang, Qianqao, primary, Ooi, Wen Fong, primary, Suling Lin, Joyce, primary, Nandi, Tannistha, primary, Yao, Xiaosai, primary, Ong, Xuewen, primary, Lee, Minghui, primary, Tay, Su Ting, primary, Keng, Angie Tan Lay, primary, Gondo Santoso, Erna, primary, Ng, Cedric Chuan Young, primary, Ng, Alvin, primary, Jusakul, Apinya, primary, Smoot, Duane, primary, Ashktorab, Hassan, primary, Rha, Sun Young, primary, Yeoh, Khay Guan, primary, Peng Yong, Wei, primary, Chow, Pierce K.H., primary, Chan, Weng Hoong, primary, Ong, Hock Soo, primary, Soo, Khee Chee, primary, Kim, Kyoung-Mee, primary, Wong, Wai Keong, primary, Rozen, Steven G., primary, Teh, Bin Tean, primary, Kappei, Dennis, primary, Lee, Jeeyun, primary, Connolly, John, primary, and Tan, Patrick, primary

Published
2023
Full Text
View/download PDF

23. Data from Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma

Author

Qamra, Aditi, primary, Xing, Manjie, primary, Padmanabhan, Nisha, primary, Kwok, Jeffrey Jun Ting, primary, Zhang, Shenli, primary, Xu, Chang, primary, Leong, Yan Shan, primary, Lee Lim, Ai Ping, primary, Tang, Qianqao, primary, Ooi, Wen Fong, primary, Suling Lin, Joyce, primary, Nandi, Tannistha, primary, Yao, Xiaosai, primary, Ong, Xuewen, primary, Lee, Minghui, primary, Tay, Su Ting, primary, Keng, Angie Tan Lay, primary, Gondo Santoso, Erna, primary, Ng, Cedric Chuan Young, primary, Ng, Alvin, primary, Jusakul, Apinya, primary, Smoot, Duane, primary, Ashktorab, Hassan, primary, Rha, Sun Young, primary, Yeoh, Khay Guan, primary, Peng Yong, Wei, primary, Chow, Pierce K.H., primary, Chan, Weng Hoong, primary, Ong, Hock Soo, primary, Soo, Khee Chee, primary, Kim, Kyoung-Mee, primary, Wong, Wai Keong, primary, Rozen, Steven G., primary, Teh, Bin Tean, primary, Kappei, Dennis, primary, Lee, Jeeyun, primary, Connolly, John, primary, and Tan, Patrick, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Data from Clinical Validation of a Customized Multiple Signature Microarray for Breast Cancer

Author

Tan, Benita K.T., primary, Tan, Lay Keng, primary, Yu, Kun, primary, Tan, Puay Hoon, primary, Lee, Ming, primary, Sii, Lang Hiong, primary, Wong, Chow Yin, primary, Ho, Gay Hui, primary, Yeo, Allen W.Y., primary, Chow, Pierce K.H., primary, Koong, Heng Nung, primary, Yong, Wei Sean, primary, Lim, Dennis T.H., primary, Ooi, London L.P.J., primary, Soo, Khee Chee, primary, and Tan, Patrick, primary

Published
2023
Full Text
View/download PDF

28. The Impact of Radiation Dose and Tumour Burden on Outcomes in Hepatocellular Carcinoma: 11-Year Experience in a 413-Patient Cohort Treated with Yttrium-90 Resin Microsphere Radioembolisation

Author

Chen, Kaina, Tong, Aaron K.T., Moe, Fiona N.N., Ng, David C.E., Lo, Richard H.G., Gogna, Apoorva, Yan, Sean X., Thang, Sue Ping, Loke, Kelvin S.H., Venkatanarasimha, Nanda Karaddi, Huang, Hian Liang, Too, Chow Wei, Ong, Timothy S.K., Yeo, Eng Xuan, Peh, Daniel Yang Yao, Ng, Ashley W.Y., Yang, Lu, Chan, Wan Ying, Chang, Jason P.E., Goh, Brian K.P., Toh, Han Chong, and Chow, Pierce K.H.

Abstract

Introduction:Transarterial radioembolisation (RE) using yttrium-90 (Y-90) microspheres is a widely used locoregional therapy for a broad spectrum of hepatocellular carcinoma (HCC) given its favourable safety profile. We evaluated the real-world outcomes of unresectable HCC treated with resin Y-90 RE and the relationship between tumour absorbed dose and subsequent curative therapy with survival. Methods:Included were consecutive patients treated with Y-90 resin microspheres RE for unresectable HCC between January 2008 and May 2019 at the National Cancer Centre Singapore/Singapore General Hospital. The outcomes were stratified by tumour burden, distribution, presence of portal vein invasion (PVI) and liver function to improve prognostication. Results:The median overall survival (OS) evaluated on 413 included patients was 20.9 months (95% CI: 18.2–24.0). More than half of the patients (214/413, 51.8%) had HCC beyond up-to-seven criteria, and 37.3% had portal vein invasion (154/413, 37.3%). Majority (71.7%) had dosimetry calculated based on the partition model. Patients who received ≥150 Gy to tumour had significantly better outcomes (OS 32.2 months, 95% CI: 18.3–46.4) than those who did not (OS 17.5 months, 95% CI: 13.7–22.7, p< 0.001). Seventy patients (17%) received curative therapies after tumour was downstaged by Y-90 RE and had better OS of 79.7 months (95% CI: 40.4 – NE) compared to those who did not receive curative therapies (OS 17.1 months; 95% CI: 13.5–20.4, p< 0.001). RE-induced liver injury was observed in 5.08% of the patients while 3.2% of the patients had possible radiation pneumonitis but none developed Grade 3–4 toxicity. For HCC without PVI, OS differed significantly with performance status, albumin-bilirubin grade, tumour distribution, and radiation dose; for HCC with PVI, Child-Pugh class and AFP were significant predictors of survival. Conclusions:Treatment outcomes for unresectable HCC using Y-90 RE were favourable. Incorporating tumour burden and distribution improved prognostication. Patients who received tumour absorbed dose above 150 Gy had better OS. Patients who subsequently received curative therapies after being downstaged by Y-90 RE had remarkable clinical outcomes.

Published
2024
Full Text
View/download PDF

32. Effect of age on the short- and long-term outcomes of patients undergoing curative liver resection for HCC

Author

Tan, Laura L.Y., primary, Chew, Valerie T.W., additional, Syn, Nicholas, additional, Tan, Ek-Khoon, additional, Koh, Ye-Xin, additional, Teo, Jin-Yao, additional, Cheow, Peng-Chung, additional, Jeyaraj, Prema Raj, additional, Chow, Pierce K.H., additional, Chan, Chung-Yip, additional, Chung, Alexander Y.F., additional, Ooi, London L.P.J., additional, and Goh, Brian K.P., additional

Published
2022
Full Text
View/download PDF

35. Genome instability is associated with ethnic differences between Asians and Europeans in hepatocellular carcinoma

Author

Kaya, Neslihan A., primary, Chen, Jianbin, additional, Lai, Hannah, additional, Yang, Hechuan, additional, Ma, Liang, additional, Liu, Xiaodong, additional, Alvarez, Jacob Santiago, additional, Liu, Jin, additional, Hillmer, Axel M., additional, Tai, David, additional, Sheng, Joe Yeong Poh, additional, Hu, Zheng, additional, Chan, Yun Shen, additional, Chow, Pierce K.H, additional, Mu, Yuguang, additional, Wuestefeld, Torsten, additional, and Zhai, Weiwei, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results